SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-192345
Filing Date
2021-06-17
Accepted
2021-06-16 19:22:01
Documents
14
Period of Report
2021-06-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d166096d8k.htm   iXBRL 8-K 55342
2 EX-4.1 d166096dex41.htm EX-4.1 7633
3 EX-10.1 d166096dex101.htm EX-10.1 9823
  Complete submission text file 0001193125-21-192345.txt   203753

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20210615.xsd EX-101.SCH 3093
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20210615_lab.xml EX-101.LAB 18138
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20210615_pre.xml EX-101.PRE 11423
7 EXTRACTED XBRL INSTANCE DOCUMENT d166096d8k_htm.xml XML 3369
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

IRS No.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 211022862
SIC: 2834 Pharmaceutical Preparations